Results 71 to 80 of about 5,463 (146)

Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review

Frontiers in Oncology
Hairy cell leukemia variant (HCL-v) is a rare and more aggressive subtype of B-cell leukemia. While it shares certain clinical features with classical hairy cell leukemia (HCL-c), HCL-v typically follows a more malignant course and responds poorly to ...
Junjun Bai, Yi Zhang, Yi Zhang, Kangqi Lv, Bei Zhang, Hongxia Wang, Zhixin Pei, Yingxin Zhao, Jingjing Gu, Huimin Wu, Qinglin Song   +10 more
doaj   +1 more source

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Morelli F, Linari S, Rapolla CM, Attanasio M, Salvianti F, Sanna A.   +5 more
europepmc   +1 more source

Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system. [PDF]

Clinics (Sao Paulo)
Bai Z, Chen J, Lan Y, Li H, Zheng R, Deng M, Pang W.   +6 more
europepmc   +1 more source

Obinutuzumab in the treatment of idiopathic refractory membranous nephropathy: an observational case series. [PDF]

Front Med (Lausanne)
Zhao X, Chang X, Wang Y, Chen D, Yu M, Zhao J, Zhu H, Mao Y, Juan C.   +8 more
europepmc   +1 more source

Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial

Drug Design, Development and Therapy
Xue-Qi Li,1 Yang Liu,1 Ze-Yu Cai,1 Tie-Gang Lv,2 Jian Hao1 1Department of Medicine, Division of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010050, China; 2Department of Medicine ...
Li XQ, Liu Y, Cai ZY, Lv TG, Hao J
doaj  

Latest advances in frontline CLL treatment from the 2025 ASH congress. [PDF]

Ann Hematol
Visentin A.
europepmc   +1 more source

The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System. [PDF]

Cancers (Basel)
Wendler J, Kasenda B, Lauer EM, Kama K, Isbell LK, Marschner D, Scherer F, Malenica N, Gloggengiesser C, Valk E, Schorb E, Illerhaus G.   +11 more
europepmc   +1 more source

Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report. [PDF]

Front Nephrol
Henriques AR, Venda J, Ferreira E, Oliveira N, Sá H.   +4 more
europepmc   +1 more source

Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus. [PDF]

Clin Exp Med
D'Amato M, Rapolla CM, Benedetti E, Bocchia M, Capochiani E, Carlomagno G, Ciofini S, Giachetti R, Maestrini G, Moretti S, Nasso D, Papini G, Pirrotta MT, Simonetti F, Santini S, Vannucchi A, Galimberti S, Sanna A.   +17 more
europepmc   +1 more source

Response to the Letter to the Editor Entitled "Reconsideration of Response Assessment in Obinutuzumab-Treated Membranous Nephropathy". [PDF]

Kidney Int Rep
Su X, Wu B, Wang L.
europepmc   +1 more source